MA40846A - Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques - Google Patents

Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques

Info

Publication number
MA40846A
MA40846A MA040846A MA40846A MA40846A MA 40846 A MA40846 A MA 40846A MA 040846 A MA040846 A MA 040846A MA 40846 A MA40846 A MA 40846A MA 40846 A MA40846 A MA 40846A
Authority
MA
Morocco
Prior art keywords
micellizing
compositions
self
treatment
well
Prior art date
Application number
MA040846A
Other languages
English (en)
Inventor
Ahmed Abd Almalik Ahmed Mohammed Daak
Glynis Daniel-Archibald
Miguel Lopez-Toledano
Frederick D Sancilio
Thorsteinn Thorsteinsson
Original Assignee
Sancilio & Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40846(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio & Company Inc filed Critical Sancilio & Company Inc
Publication of MA40846A publication Critical patent/MA40846A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
MA040846A 2014-10-10 2015-10-08 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques MA40846A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462062638P 2014-10-10 2014-10-10
US201462062652P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10

Publications (1)

Publication Number Publication Date
MA40846A true MA40846A (fr) 2017-09-05

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040846A MA40846A (fr) 2014-10-10 2015-10-08 Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques

Country Status (8)

Country Link
EP (1) EP3212236A1 (fr)
BR (1) BR112017007428A2 (fr)
CA (1) CA2963952C (fr)
CL (1) CL2017000867A1 (fr)
MA (1) MA40846A (fr)
MX (2) MX2017004324A (fr)
WO (1) WO2016057915A1 (fr)
ZA (1) ZA201702385B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017193563A1 (fr) * 2015-11-13 2017-11-16 深圳君圣泰生物技术有限公司 Composition, et application et préparation pharmaceutique de cette dernière
CN106692973A (zh) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
WO2018027278A1 (fr) 2016-08-12 2018-02-15 Pharmako Biotechnologies Pty Limited Compositions d'oméga-3 et méthodes associées
EP3579829B1 (fr) * 2017-02-07 2026-03-25 Fresenius Kabi Deutschland GmbH Efficacité à long terme du traitement d'une maladie du foie par epa et dha
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
IT201900007202A1 (it) * 2019-05-24 2020-11-24 Pavia Farm S R L Composizione a base di vitamine liposolubili ad elevato assorbimento enterico
MX2022001238A (es) 2019-08-13 2022-07-13 Team Foods Colombia Sa Composicion lipidica que comprende antioxidantes y polifenoles naturales como alternativa no farmacologica para el tratamiento y la prevencion de nafld.
CN115737555B (zh) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 一种千金藤素自微乳组合物、制剂及其制备方法
CN117730823A (zh) * 2022-09-20 2024-03-22 上海中医药大学 原发性硬化性胆管炎合并炎症性肠病的造模方法
WO2026030644A1 (fr) * 2024-07-31 2026-02-05 Caper Labs, Inc. Thérapie à l'acide arachidonique pour le traitement de la neutropénie

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2433630A4 (fr) * 2009-05-22 2014-01-08 Mochida Pharm Co Ltd Composition auto-émulsifiante d'acide gras 3
AR082930A1 (es) * 2010-09-08 2013-01-16 Pronova Biopharma Norge As Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
WO2013093630A2 (fr) * 2011-12-22 2013-06-27 Pronova Biopharma Norge As Capsules à libération retardée de gélatine/alginate comprenant des acides gras oméga-3, et leurs procédés et leurs utilisations
IN2014DN08449A (fr) * 2012-03-30 2015-05-08 Sancilio & Company Inc

Also Published As

Publication number Publication date
CL2017000867A1 (es) 2017-11-03
EP3212236A1 (fr) 2017-09-06
MX2017004324A (es) 2017-07-04
WO2016057915A1 (fr) 2016-04-14
BR112017007428A2 (pt) 2017-12-19
MX2020002238A (es) 2020-07-13
ZA201702385B (en) 2020-12-23
CA2963952A1 (fr) 2016-04-14
CA2963952C (fr) 2023-10-17

Similar Documents

Publication Publication Date Title
MA40846A (fr) Compositions d'acides gras et d'esters d'acides gras auto-micellisantes, ainsi que leur utilisation dans le traitement d'états pathologiques
EP2981551A4 (fr) Méthodes et compositions pour le traitement de la maladie de pompe
EP2822923A4 (fr) Préparation d'acides carboxyliques alpha,bêta-insaturés et de leurs esters
MY165048A (en) Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
EP2836226A4 (fr) Compositions et méthodes pour le traitement d'hémoglobinopathies
PL3349783T3 (pl) Kompozycje i sposoby do leczenia chorób
HUE051476T2 (hu) Kannabidiolsav alkalmazása az epilepszia kezelésében
PL2444081T3 (pl) Kompozycja do leczenia chorób zapalnych, zawierająca kwas bosweliowy i kannabidiol
EP2819687A4 (fr) Compositions et méthodes de traitement d'une maladie vasculaire périphérique
EP3661600A4 (fr) Analogues d'acides gras et leur utilisation dans le traitement des états liés au syndrome métabolique
EP2887923A4 (fr) Formulation ophtalmique d'acide gras ou lipidique de polyoxyle, et traitement de pathologies oculaires
CY1123942T1 (el) Συνθεσεις ωμεγα-3 λιπαρων οξεων για τη θεραπεια ασθενειων που επιφερουν βλαβη στο νευρικο συστημα
EP2827868A4 (fr) Compositions pharmaceutiques comprenant des esters d'acides gras
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
HUE046239T2 (hu) Zsírsav keverékek gyulladásos megbetegedések kezelésében való alkalmazásra
IL247529A0 (en) Lipoic acid choline ester compositions and methods of use
FR3030231B1 (fr) Utilisation d'un ester d'acide gras pour matifier la peau et composition comprenant cet ester
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
EP2947141A4 (fr) Micro-organismes produisant de l'acide docosahexaénoïque et leur utilisation
MA52644A (fr) Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
EP3318261A4 (fr) Utilisation de l'acide zolédronique pour préparer un médicament pour le traitement de la stéatose hépatique
EP2964750A4 (fr) Méthodes et compositions utilisables en vue du traitement et/ou de la prévention du diabète de type 1
EP3316874A4 (fr) Compositions topiques et injectables de résiquimod pour le traitement d'affections cutanées néoplasiques